Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Inclusion Criteria: 1. To provide a signed and dated, written informed consent. 2. Age ≥ 18 years old 3. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory 4. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated，at least one line chemotherapy and progress again 5. Predicted life expectancy ≥ 12 weeks 6. Adequate organ system function: 7. Patient must have measurable disease according to RECIST 1.1. - Exclusion Criteria: 1. Spinal cord compression or meningeal metastasis 2. Not Recover from AEs caused by previous treatment yet 3. A history of stroke or intracranial hemorrhage within 6 months prior to initial dosing. 4. Any severe or poorly controlled systemic disease per investigator's judgment .active infections, including but not limited to hepatitis B (HBV), hepatitis C HCV, and human immunodeficiency HIV